
Annual report 2024
added 02-21-2026
Evogene Ltd. EPS Ratio 2011-2026 | EVGN
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Evogene Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -0.83 | -0.7 | -0.81 | -0.81 | -0.77 | -0.68 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.68 | -0.83 | -0.767 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.68 | 2.44 % | $ 429 M | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
Kamada Ltd.
KMDA
|
-0.05 | $ 8.81 | 1.73 % | $ 260 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Adagene
ADAG
|
-0.59 | $ 3.26 | 0.62 % | $ 183 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.28 | -2.62 % | $ 7.89 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-0.15 | - | -19.68 % | $ 18.4 M | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
Aptorum Group Limited
APM
|
-0.78 | $ 0.79 | -1.29 % | $ 4.31 M | ||
|
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
0.001 | $ 0.88 | -1.43 % | $ 442 M | ||
|
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 224.42 | -2.52 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Arena Pharmaceuticals
ARNA
|
-10.1 | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
-0.54 | $ 4.13 | 0.12 % | $ 352 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | ||
|
Aytu BioScience
AYTU
|
-2.16 | $ 2.36 | 2.27 % | $ 14.8 M | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | ||
|
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | ||
|
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | ||
|
Codexis
CDXS
|
-0.89 | $ 1.17 | -0.85 % | $ 85.9 M | ||
|
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 110.12 | -0.28 % | $ 27.2 B | ||
|
Amneal Pharmaceuticals
AMRX
|
-0.38 | $ 14.49 | -0.75 % | $ 4.48 B | ||
|
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M |